Cardiac Troponin Market Size, Share and Global Trend By Type (Troponin T, Troponin I), By Site Of Testing (Laboratory-based, Point-of-care), By Application (Acute Coronary Syndrome, Myocardial Infarction, Congestive Heart Failure), By End User (Hospitals, Diagnostic Centers, Homecare Settings) and Geography Forecast till 2030

The diagnosis of myocardial infarction is dependent on the presence of chest pain or typical ST segment, T wave abnormalities on the 12 lead electrocardiogram (ECG) and a rise in the serum concentrations of cardiac muscle enzymes. Cardiac troponin T (cTnT) and troponin I (cTnI) are cardiac regulatory proteins that control the calcium-mediated interaction between actin and myosin.

Cardiac troponins are indicators of myocardial necrosis, and due to their high cardiac-specificity, they have beed used as a preferred biomarker for the diagnosis of myocardial infarction. Cardiac troponins are majorly detected in the serum by the usage of monoclonal antibodies to epitopes of cTnI and cTnT. According to the World Health Organization, 32.4 million myocardial infarctions and strokes are reported globally every year.

To gain extensive insights into the market, Request for Customization

The rising demand for cardiac biomarkers for diagnosis of cardiovascular diseases and the increasing prevalence of acute coronary syndrome are some of the factors driving the growth of the cardiac troponin market. Patients suffering from acute critical heart conditions require fast results and quick diagnosis.

This has spiked the demand for advanced cardiac troponins by the healthcare providers globally. This rising demand, combined with increasing R&D by players to introduce new products are anticipated to drive the growth of the global cardiac troponin market during the forecast period.

However, lack of skilled personell required for collecting samples and inadequate reimbursements policies are some of the factors restraining the growth of the global cardiac troponin market.

Key Players Covered

Some of the major companies that are present in the global cardiac troponin market are are F. Hoffmann-La Roche Ltd, Abbott, Siemens Healthcare GmbH, LSI Medience Corporation, Eurolyser Diagnostica GmbH,Response Biomedical Corp., Tulip Diagnostics (P) Ltd, Beckman Coulter, Inc., bioMérieux SA. and other players

SEGMENTATION

In 2018, among type, Troponin T dominated the global cardiac Troponin market due to lesser cost of the Troponin test and implementation of the Patient Protection and Affordable Care Act (ACA) in the different regions globally. This segment is projected to grow at comparatively higher CAGR during the forecast period.

Key Insights

• Prevalence of Cardiac Diseases by Key Regions, 2018


• Regulatory Scenario by Key Countries


• Recent Industry Developments Such as Partnerships, Mergers, and Acquisitions

Regional Analysis

North America dominated the global cardiac troponin market in 2018. Europe and the Asia Pacific are anticipated to grow at a significant CAGR due to increasing prevalence of cardiovascular diseases, increasing per capita healthcare expenditure and improving access to advanced cardiac troponin diagnostics in emerging countries. Additionally, increasing prevalence of comorbidities such as obesity and hypertension and rising demand for preventive medical care are some the factors driving the growth of the cardiac troponin market in the Asia Pacific region. The Latin America and Middle East & Africa have anticipated to gain relativity smaller market share and comparatively low CAGR due to increasing demand for the diagnostics, increasing healthcare expenditure, and a rapidly developing healthcare infrastructure.

Cardiac Troponin Industry Developments

• In June 2018, Beckman Coulter, Inc., received Health Canada clearance for high sensitivity troponin (hsTnI) assay, Access hsTnI, that aids in diagnosing myocardial infarction for patients presenting with chest pain or other ischemic symptoms.
• In October 2017, Fujirebio Diagnostics, Inc., announced the CE marking of the Lumipulse G CK-MB immunoassay, which can be used as an aid in the diagnosis of Acute Myocardial Infarction (AMI) or as a marker of reinfarction.